The development of anticancer therapies that target apoptosis pathways may be hampered by resistance of certain tumor cells to death signals. New findings show that tumor cells lacking the pro-apoptotic protein Bax are resistant to apoptosis induced by the death ligand TRAIL, but that chemotherapeutic drugs can restore their sensitivity to TRAIL. (pages 274–281)
This is a preview of subscription content, log in via an institution to check access.
References
Reed, J.C. Apoptosis-based therapies. Nature Rev. Drug Dev. 1, 111–121 (2002).
Nicholson, D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810–816 (2000).
LeBlanc, H. et al. Tumor cell resistance to death receptor induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Med. 8, 274–281 (2002).
Ashkenazi, A. & Dixit, V.M. Death receptors: signaling and modulation. Science 281, 1305–1308 (1998).
Salvesen, G.S. & Dixit, V.M. Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. USA 96, 10964–10967 (1999).
Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J.C. & Perucho, M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl. Acad. Sci. USA 97, 10872–10877 (2000).
Scaffidi, C. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675–1687 (1998).
Desagher, S. et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell. Biol. 144, 891–901 (1999).
Deng, Y., Lin, Y. & Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33–45 (2002).
Wei, M.C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730 (2001).
Zhang, L., Yu, J., Park, B.H., Kinzler, K.W. & Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 290, 989–992 (2000).
Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157–163 (1999).
Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999).
Soengas, M.S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207–211 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roth, W., Reed, J. Apoptosis and cancer: When BAX is TRAILing away. Nat Med 8, 216–218 (2002). https://doi.org/10.1038/nm0302-216
Issue Date:
DOI: https://doi.org/10.1038/nm0302-216
- Springer Nature America, Inc.
This article is cited by
-
Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer
Cell Death & Disease (2022)
-
Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by ‘Iturin A’ a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium
Scientific Reports (2017)
-
Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway
Science China Life Sciences (2017)
-
The Novel Heterocyclic Trioxirane [(1,3,5-Tris Oxiran-2-yl)Methyl)-1,3,5-Triazinane-2,4,6-Trione (TATT)] Exhibits a Better Anticancer Effect than Platinum-Based Chemotherapy by Induction of Apoptosis and Curcumin Further Enhances its Chemosensitivity
Cell Biochemistry and Biophysics (2014)
-
Downregulation of programmed cell death 4 (PDCD4) in tumorigenesis and progression of human digestive tract cancers
Tumor Biology (2013)